Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs

  1. Rudolf Jaenisch a , c , 1
  1. aThe Whitehead Institute for Biomedical Research, Cambridge, MA 02142; and
  2. bComputational and Systems Biology Program and
  3. cDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142
  1. Contributed by Rudolf Jaenisch, April 8, 2010 (sent for review March 27, 2010)

Abstract

Human and mouse embryonic stem cells (ESCs) are derived from blastocyst-stage embryos but have very different biological properties, and molecular analyses suggest that the pluripotent state of human ESCs isolated so far corresponds to that of mouse-derived epiblast stem cells (EpiSCs). Here we rewire the identity of conventional human ESCs into a more immature state that extensively shares defining features with pluripotent mouse ESCs. This was achieved by ectopic induction of Oct4, Klf4, and Klf2 factors combined with LIF and inhibitors of glycogen synthase kinase 3β (GSK3β) and mitogen-activated protein kinase (ERK1/2) pathway. Forskolin, a protein kinase A pathway agonist which can induce Klf4 and Klf2 expression, transiently substitutes for the requirement for ectopic transgene expression. In contrast to conventional human ESCs, these epigenetically converted cells have growth properties, an X-chromosome activation state (XaXa), a gene expression profile, and a signaling pathway dependence that are highly similar to those of mouse ESCs. Finally, the same growth conditions allow the derivation of human induced pluripotent stem (iPS) cells with similar properties as mouse iPS cells. The generation of validated “naïve” human ESCs will allow the molecular dissection of a previously undefined pluripotent state in humans and may open up new opportunities for patient-specific, disease-relevant research.

Footnotes

  • 1To whom correspondence may be addressed. E-mail: hanna{at}wi.mit.edu or jaenisch{at}wi.mit.edu.
  • Author contributions: J.H. and R.J. designed research; J.H., A.W.C., K.S., J.K., C.J.L., F.S., and J.M. performed research; J.H., J.P.C., and B.W.C. contributed new reagents/analytic tools; J.H., A.W.C., and K.S. analyzed data; and J.H., K.S., and R.J. wrote the paper.

  • Conflict of interest statement: R.J. is a cofounder of Fate Therapeutics and an adviser to Stemgent. R.J. and J.H. have filed a patent application describing the results and concepts presented herein.

  • Data deposition: The gene array datasets reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE 21222).

  • This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1004584107/-/DCSupplemental.